Hermetica Superfood Encyclopedia
The Short Answer
Ubiquinol (CoQH2) is the fully reduced, electron-rich form of Coenzyme Q10 that functions simultaneously as a mitochondrial electron carrier within Complexes I–III of the respiratory chain and as a membrane-soluble free radical scavenger capable of directly donating electrons to neutralize reactive oxygen species and regenerating vitamin E. In a clinical endothelial function meta-analysis of 18 studies, ubiquinol supplementation at 100–200 mg/day produced statistically significant improvements in flow-mediated dilation (FMD) of +1.28–1.34 percentage points over baseline, with superior outcomes compared to ubiquinone attributable to its 3–8× greater bioavailability in older adults.
CategoryCompound
GroupMineral
Evidence LevelPreliminary
Primary Keywordubiquinol benefits
Ubiquinol — botanical close-up
Health Benefits
**Mitochondrial ATP Production**
Ubiquinol shuttles electrons between NADH dehydrogenase (Complex I), succinate dehydrogenase (Complex II), and cytochrome bc1 (Complex III) via the Q cycle, sustaining the proton gradient required for ATP synthase activity and cellular energy homeostasis.
**Cardiovascular Endothelial Function**
In a study of 14 chronic heart failure patients with reduced ejection fraction, 400 mg/day ubiquinol for 3 months significantly improved endothelial function, and pooled analysis of 18 trials confirms consistent FMD improvements of approximately +1.3 percentage points, reflecting reduced oxidative stress in vascular endothelium.
**Lipid Peroxidation Inhibition**
Ubiquinol intercepts peroxyl radicals in lipid bilayers and LDL particles before chain propagation occurs, directly reducing oxidized lipid byproducts and protecting membrane integrity more potently than ubiquinone, which lacks the reactive hydroxyl groups required for direct radical quenching.
**Anti-inflammatory and Anti-thrombotic Activity**
In 36 patients with antiphospholipid syndrome, 200 mg/day ubiquinol for one month reduced pro-thrombotic and pro-inflammatory mediators, increased mitochondrial size, and upregulated mitochondrial biogenesis genes including PGC-1α, suggesting epigenetic and structural cellular remodeling.
**Statin-Induced CoQ10 Depletion Mitigation**
HMG-CoA reductase inhibitors (statins) block the mevalonate pathway, suppressing both cholesterol and endogenous CoQ10 biosynthesis; ubiquinol supplementation at 100–200 mg/day has been proposed to replenish tissue CoQ10 levels and potentially reduce statin-associated myopathy, though large-scale RCT evidence remains inconclusive.
**Fatigue Reduction**
Preliminary clinical data indicate that ubiquinol supplementation relieves symptoms of mild physical and mental fatigue in healthy adults, consistent with its role in enhancing mitochondrial respiratory efficiency and reducing oxidative burden in skeletal muscle and neural tissue.
**Vitamin E Regeneration**
Ubiquinol directly reduces tocopheroxyl radicals back to α-tocopherol at membrane surfaces, functioning as a co-antioxidant that amplifies the effective antioxidant capacity of dietary vitamin E and extends its protective action against lipid oxidation.
Origin & History
Natural habitat
Ubiquinol is not geographically cultivated but is an endogenously synthesized molecule found in virtually all human cells, with highest concentrations in metabolically active tissues such as the heart, liver, and kidneys. It is biosynthesized via the mevalonate (HMG-CoA reductase) pathway using precursors including tyrosine and the isoprenoid side chain, with endogenous production peaking in the second decade of life and declining progressively thereafter. Commercial ubiquinol supplements are manufactured through yeast fermentation or chemical synthesis followed by reduction of ubiquinone, and are formulated in lipid-based matrices to preserve the reduced state and enhance gastrointestinal absorption.
“Ubiquinol has no traditional use history in pre-modern medicine systems, as its identity and biological role were entirely unknown prior to the mid-20th century; CoQ10 (ubiquinone) was first isolated from bovine heart mitochondria by Frederick Crane at the University of Wisconsin in 1957, and its redox partner ubiquinol was characterized shortly thereafter through the foundational work of Peter Mitchell, whose chemiosmotic hypothesis (Nobel Prize, 1978) defined the Q cycle mechanism. Clinical interest in CoQ10 supplementation began in Japan in the 1970s and 1980s, where ubiquinone was approved as a pharmaceutical adjunct for heart failure, making Japan one of the earliest and most extensive markets for CoQ10 therapeutics. The shift toward supplementing the ubiquinol form specifically gained momentum in the early 2000s following stabilization technology advances by Kaneka Corporation (Japan) that allowed the inherently unstable reduced form to be manufactured and stored reliably in commercial supplements. Unlike many botanical ingredients with centuries of ethnobotanical documentation, ubiquinol's entire history is grounded in modern biochemistry and clinical pharmacology, representing a paradigm of evidence-based nutritional supplementation developed through reductionist biochemical research rather than empirical traditional observation.”Traditional Medicine
Scientific Research
The clinical evidence base for ubiquinol specifically — as distinct from ubiquinone — is growing but remains moderate in volume, with most high-quality data coming from small-to-medium randomized controlled trials (typically 14–100 participants) and comparative bioavailability studies rather than large multi-center phase III trials. A pooled analysis encompassing 18 clinical studies documented consistent improvements in endothelial flow-mediated dilation with ubiquinol supplementation, lending reasonable confidence to cardiovascular endpoint data, though heterogeneity in dose, duration, and population limits definitive conclusions. Head-to-head pharmacokinetic trials in older adults reliably demonstrate 3–8× higher area under the curve (AUC) plasma concentrations for ubiquinol versus equimolar ubiquinone, providing mechanistic justification for dose equivalence claims; however, clinical superiority in hard outcomes (mortality, MACE) has not yet been demonstrated in adequately powered trials. Research on antiphospholipid syndrome (n=36) and chronic heart failure (n=14) shows promising mechanistic and surrogate-endpoint results, but these sample sizes are insufficient to establish clinical efficacy standards, and the field would benefit substantially from replication in larger, pre-registered RCTs.
Preparation & Dosage
Traditional preparation
**Softgel Capsules (standard form)**
100–200 mg/day for general antioxidant support and cardiovascular health maintenance; take with a fat-containing meal to maximize lymphatic absorption of this highly lipophilic molecule
**High-Dose Therapeutic Softgels**
300–400 mg/day used in clinical trials for chronic heart failure or significant mitochondrial dysfunction; divide into two daily doses (e
g., 200 mg morning, 200 mg evening) to maintain more consistent plasma levels.
**Statin Co-supplementation Protocol**
100–200 mg/day ubiquinol to counteract statin-mediated HMG-CoA reductase pathway depletion of endogenous CoQ10; timing alongside the statin dose is common in practice though not formally standardized
**Lipid-Matrix Formulations**
Ubiquinol is chemically unstable and prone to oxidation back to ubiquinone; high-quality products use proprietary lipid solubilization systems (e.g., Kaneka QH™ in sesame oil or sunflower oil matrices) to maintain the reduced form through shelf life.
**Standardization**
Pharmaceutical-grade ubiquinol is typically standardized to ≥98% CoQH2 content; verify certificate of analysis for reduced-form purity, as poorly stabilized products may deliver predominantly ubiquinone.
**Elderly Population Dosing**
100 mg/day ubiquinol approximates the plasma elevation achieved by 300–400 mg/day ubiquinone in this demographic
Adults over 50 benefit disproportionately from ubiquinol over ubiquinone due to impaired endogenous reduction capacity; .
**Timing Note**
10–15 g of dietary fat compared to fasted administration
Fat co-ingestion is essential — bioavailability increases 3–5× when taken with a meal containing at least .
Nutritional Profile
Ubiquinol is not a macronutrient and contributes negligible caloric value; it functions as a fat-soluble bioactive compound rather than a classical nutrient, though it is essential for mitochondrial function in all aerobic organisms. Dietary concentrations in food sources are low: organ meats (heart, liver, kidney) contain approximately 3–6 mg CoQ10 per 100 g (predominantly as ubiquinone in raw tissue), beef muscle contains 1–3 mg/100 g, sardines and mackerel contain 2–4 mg/100 g, and plant sources including spinach and broccoli contain <1 mg/100 g — far below supplemental doses of 100–400 mg. The redox ratio of ubiquinol to total CoQ10 in healthy young adults is approximately 95–97% in plasma, declining toward 80–90% with age and oxidative stress-related conditions; this ratio serves as a clinically informative biomarker of systemic oxidative stress. Bioavailability from food is significantly lower than from supplements due to the food matrix, cooking-induced oxidation of ubiquinol to ubiquinone, and the comparatively small absolute amounts present; supplemental ubiquinol in lipid matrices achieves peak plasma concentrations (Tmax) at approximately 5–6 hours post-dose.
How It Works
Mechanism of Action
At the molecular level, ubiquinol (CoQH2) donates two electrons and two protons within the mitochondrial inner membrane Q cycle: at the Qo site of Complex III (cytochrome bc1), it is oxidized to semiquinone and then ubiquinone, releasing protons into the intermembrane space to sustain the electrochemical gradient driving ATP synthase, while the liberated electrons reduce cytochrome c for downstream delivery to Complex IV. As a chain-breaking antioxidant, the two hydroxyl groups on its benzoquinone ring donate hydrogen atoms to peroxyl and hydroxyl radicals, generating the relatively stable ubisemiquinone radical that is efficiently recycled back to ubiquinol by mitochondrial and cytosolic reductases, including NAD(P)H-dependent enzymes. Ubiquinol also serves as an obligate cofactor for dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in de novo pyrimidine biosynthesis, linking mitochondrial respiratory function to nucleotide production essential for rapidly proliferating cells. Additionally, ubiquinol modulates redox-sensitive signaling by suppressing protein kinase C activation and inhibiting NADPH oxidase-mediated superoxide generation, reducing downstream NF-κB-dependent inflammatory gene transcription and protecting endothelial nitric oxide synthase (eNOS) activity.
Clinical Evidence
The most rigorously characterized clinical outcomes for ubiquinol center on endothelial function (FMD), with an aggregate of 18 studies demonstrating statistically significant improvements of approximately +1.28–1.34 percentage points in flow-mediated dilation at doses of 100–200 mg/day, a magnitude considered clinically meaningful for cardiovascular risk reduction. In a 3-month open-label trial of 14 chronic heart failure patients (reduced ejection fraction), 400 mg/day ubiquinol improved endothelial function, while a 1-month RCT in 36 antiphospholipid syndrome patients using 200 mg/day demonstrated reduced pro-thrombotic biomarkers, increased mitochondrial number, and upregulation of PGC-1α and TFAM biogenesis genes. Bioavailability trials consistently show ubiquinol achieves significantly higher plasma CoQ10 levels than ubiquinone at equivalent doses, an effect most pronounced in individuals over 50 due to age-related decline in the hepatic reduction capacity needed to convert ubiquinone to ubiquinol. Confidence in surrogate-marker cardiovascular benefits is moderate-to-good; confidence in hard clinical outcomes (hospitalization rates, mortality) remains limited by the absence of adequately powered phase III trials specifically using ubiquinol.
Safety & Interactions
Ubiquinol is well-tolerated across the clinically studied dose range of 100–400 mg/day, with adverse effects limited to mild, transient gastrointestinal disturbances including nausea, loose stools, epigastric discomfort, and rarely vomiting, predominantly when taken on an empty stomach; these effects resolve with dose reduction or food co-administration. The most clinically significant drug interaction involves HMG-CoA reductase inhibitors (statins): statins deplete endogenous CoQ10 by blocking the shared mevalonate biosynthetic pathway, and ubiquinol supplementation is commonly used to replenish these levels; ubiquinol may theoretically attenuate statin-associated myopathy, though this interaction is pharmacologically additive rather than antagonistic and does not contraindicate co-use. There is a theoretical concern that CoQ10 may modestly reduce the anticoagulant effect of warfarin due to structural similarity to vitamin K2; patients on warfarin therapy should monitor INR when initiating or discontinuing ubiquinol supplementation and consult their prescribing physician. Safety data in pregnancy and lactation are insufficient to make formal recommendations; given endogenous ubiquinol is present in human breast milk and placental tissue, low supplemental doses are unlikely to pose risk, but conservative clinical guidance recommends avoiding supplementation during pregnancy and lactation unless medically directed, and no upper tolerable intake level has been formally established by regulatory bodies.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Coenzyme Q10 reduced formCoQH2Reduced CoQ10DihydroubiquinoneKaneka QH
Frequently Asked Questions
What is the difference between ubiquinol and ubiquinone?
Ubiquinol (CoQH2) is the fully reduced, electron-rich form of Coenzyme Q10, while ubiquinone is the oxidized form; both are interconverted within cells, but ubiquinol is the predominant antioxidant-active species in plasma. The key practical difference is absorption: clinical pharmacokinetic studies demonstrate that ubiquinol achieves 3–8× higher plasma AUC compared to equimolar ubiquinone, particularly in adults over 50 whose liver has diminished capacity to reduce ubiquinone to the active ubiquinol form.
How much ubiquinol should I take per day?
Clinical trials supporting cardiovascular and endothelial function benefits used doses of 100–200 mg/day, with 400 mg/day studied in chronic heart failure patients for 3 months; most healthy adults seeking antioxidant and energy support are well-served by 100–200 mg daily. Ubiquinol should be taken with a fat-containing meal to maximize its lipophilic absorption, and dose should be divided (e.g., 100 mg twice daily) when using higher therapeutic ranges to maintain stable plasma levels throughout the day.
Does ubiquinol help with statin side effects?
Statins inhibit the HMG-CoA reductase enzyme in the mevalonate pathway, which simultaneously reduces both cholesterol and endogenous CoQ10 biosynthesis, potentially contributing to the muscle pain (myopathy) experienced by some statin users. Supplementing with 100–200 mg/day ubiquinol can replenish depleted tissue CoQ10 levels effectively; however, while mechanistically sound and clinically practiced, large-scale RCT evidence specifically demonstrating ubiquinol's efficacy in reducing statin myopathy symptoms remains inconclusive and awaits adequately powered trials.
Is ubiquinol safe for long-term use?
Available clinical evidence from trials up to several months in duration indicates ubiquinol is well tolerated at doses of 100–400 mg/day, with adverse effects limited to mild gastrointestinal symptoms (nausea, loose stools) that typically resolve when taken with food. No serious adverse events or toxicity signals have been identified in human studies; however, formal long-term safety data beyond 12 months from controlled trials are limited, and individuals on warfarin should monitor INR due to a theoretical interaction with the anticoagulation pathway related to CoQ10's structural similarity to vitamin K2.
At what age should I switch from CoQ10 to ubiquinol?
There is no universal consensus cutoff age, but the bioavailability advantage of ubiquinol becomes increasingly relevant from approximately age 40–50 onward, as hepatic and systemic capacity to reduce ubiquinone to ubiquinol declines measurably with age. Pharmacokinetic studies confirm that adults over 50 achieve significantly lower plasma CoQ10 levels from standard ubiquinone doses compared to younger subjects, making 100 mg/day ubiquinol roughly equivalent in plasma exposure to 300–400 mg/day ubiquinone in older demographics — a meaningful cost-efficiency consideration.
Does ubiquinol improve absorption compared to ubiquinone?
Ubiquinol is the reduced form of CoQ10 and is generally considered more bioavailable than ubiquinone, particularly for individuals with compromised digestive function or those taking medications that affect nutrient absorption. Studies suggest ubiquinol achieves higher blood levels with lower doses, though absorption rates vary significantly based on individual factors like age, gut health, and whether it's taken with fat-containing meals. Both forms ultimately convert to the other as needed by the body, so the practical advantage depends on individual absorption capacity.
Can ubiquinol support energy production during intense exercise or athletic activity?
Ubiquinol plays a critical role in mitochondrial ATP production by facilitating electron transfer in the respiratory chain, which theoretically supports energy availability during high-demand activities. Limited research suggests supplementation may benefit endurance athletes, though evidence remains mixed and individual responses vary considerably. Most athletic benefits appear modest unless baseline CoQ10 status is depleted, making ubiquinol more relevant for recovery and sustained performance than acute energy enhancement.
Should I take ubiquinol if I have naturally low CoQ10 levels due to age or medication?
Ubiquinol supplementation may be particularly beneficial for older adults or those taking statins, which deplete endogenous CoQ10 production and impair the body's ability to convert ubiquinone to the active ubiquinol form. Individuals over 50, those with cardiovascular conditions, or chronic disease sufferers typically show lower tissue CoQ10 levels and may experience greater benefit from ubiquinol than from ubiquinone. A healthcare provider can assess whether your specific situation warrants supplementation based on symptoms, medications, and individual risk factors.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w ubiquinol-coenzyme-q10-reduced-form-coqh2 curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
